What is Raremark?
Raremark operates at the intersection of patient advocacy and biopharmaceutical innovation. The company constructs research networks that aggregate anonymized and aggregated patient data, offering biopharmaceutical firms insights previously unavailable. This data is crucial for advancing clinical development and expediting the path to market for treatments targeting rare diseases. Raremark's platform employs machine learning and behavioral science to engage and retain patients, thereby enhancing health literacy and fostering informed participation in medical research. The growing knowledge base of patient experiences is a key asset, strengthening the company's value proposition over time. Headquartered in London, UK, Raremark also maintains offices in Boston, New York, and Ukraine.
How much funding has Raremark raised?
Raremark has raised a total of $6.9M across 3 funding rounds:
Private Equity
$1M
Other Financing Round
$2.1M
Series A
$3.8M
Private Equity (2016): $1M, investors not publicly disclosed
Other Financing Round (2018): $2.1M, investors not publicly disclosed
Series A (2018): $3.8M supported by Albion Capital Group, Oltre Venture, Ananda Ventures, and Cass Entrepreneurship Fund
Key Investors in Raremark
Albion Capital Group
Albion Capital Group is an investment firm that likely focuses on providing growth capital to innovative companies, potentially within the healthcare or technology sectors, given Raremark's business model.
Oltre Venture
Oltre Venture is an investment entity that has participated in Raremark's funding rounds, contributing to the company's overall capital structure and strategic development.
Cass Entrepreneurship Fund
The Cass Entrepreneurship Fund is a venture capital fund dedicated to investing in high-potential, revenue-generating businesses, indicating a focus on supporting scalable and impactful ventures like Raremark.
What's next for Raremark?
With a significant recent strategic investment and substantial total capital raised, Raremark is poised for accelerated growth and expanded impact in the rare disease sector. The company's unique approach to patient data aggregation and engagement, powered by advanced technologies, positions it as a critical partner for biopharmaceutical companies seeking to develop effective treatments. Future endeavors will likely focus on further scaling its research networks, enhancing its data analytics capabilities, and deepening its relationships within the rare disease community. This strategic financing will undoubtedly fuel Raremark's vision of a future where all rare diseases are treated.
See full Raremark company page
